Bioimpacts最新文献

{"title":"Performance of protein N linear epitopes in serodiagnosis of COVID-19 infection.","authors":"Sahar Farajnia, Nazli Khajenasiri, Safar Farajnia, Farzin Seyrafi, Nasim Bakhtiyari","doi":"10.34172/bi.30232","DOIUrl":"10.34172/bi.30232","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Despite the efforts to contain the spread of COVID-19, the virus remains in circulation, posing a considerable risk to populations across the globe. Hence, rapid and early detection of this infection is essential for effective disease control. The nucleocapsid (N) protein of the virus serves as a primary target for antibody response during CoV2 infections, making it a potential candidate for COVID-19 detection. This study aims to prepare and evaluate the linear epitopes of the N protein for serodiagnosis of COVID-19 infection.</p><p><strong>Methods: </strong>The linear epitope of the N protein gene was identified using ABCpred, BCpred, and IEDB. These epitopes were subsequently amplified by RT-PCR, cloned, and expressed in soluble form in the <i>E. coli</i> BL21 strain. The recombinant protein was purified using the Ni-NTA column. The reactivity of purified N protein with sera from SARS-CoV-2 patients was analyzed using an ELISA assay.</p><p><strong>Results: </strong>Sequencing analysis demonstrated the successful cloning of the linear epitopes of the N protein into the PET-28a vector, along with an n-terminal His-tag fusion. The recombinant protein was produced in <i>E. coli</i> BL21 and purified with a Ni-NTA column. The analysis demonstrated that the N protein linear epitopes were expressed in a soluble form and appeared as a 50 kDa band in the SDS-PAGE. Examination for the reactivity of the purified N protein with the COVID-19 patient's sera by ELISA revealed that the N protein recognizes the infection with high sensitivity and specificity.</p><p><strong>Conclusion: </strong>The results of this study indicated that linear epitopes of the SARS-CoV-2 N protein are highly immunogenic and could be exploited for serodiagnosis of infection in patients suspected of COVID-19 infection.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30232"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.","authors":"Hamideh Abbaspour Kasgari, Siavash Moradi, Ahmad Alikhani, Nasim Ahmadian","doi":"10.34172/bi.29952","DOIUrl":"10.34172/bi.29952","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Drug repurposing as a low-cost, time-saving, and often less risky strategy has been attractive for the treatment of coronavirus disease 2019 (COVID-19) during the pandemic. This trial aimed to evaluate the effectiveness of dolutegravir, an HIV-1 integrase inhibitor, in admitted patients with moderate COVID-19.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled clinical trial assessing the efficacy of dolutegravir in adults admitted to a hospital in Ghaemshahr, Mazandaran Province, Iran. Patients aged 18-80 years with early symptoms of moderate COVID-19, which was confirmed based on reverse transcription polymerase chain reaction (RT-PCR) and/or chest computed tomography (CT) scan, were considered to be included in this study. Patients were randomly assigned in a 1:1 ratio to receive 50 mg dolutegravir plus the standard treatment regimen or the same value of placebo plus the standard treatment regimen, daily for 7 days. The standard treatment regimen was remdesivir 200 mg on day 1 followed by 100 mg for five days or until discharge. The primary endpoint was recovery 10 days after the beginning of the study.</p><p><strong>Results: </strong>Between August 22 and October 23, 2021, of 120 patients who were enrolled, 93 patients were randomly assigned to receive 50 mg dolutegravir (n=46) or the placebo regimen (n=47). No significant difference was observed between the two intervention groups based on the obtained results including frequency of respiratory modes during the first five days of admission, respiratory rate, and O₂ saturation during six time periods.</p><p><strong>Conclusion: </strong>The results showed that in adult patients admitted to the hospital with moderate COVID-19, treatment with dolutegravir was not associated with improvement in clinical recovery. Larger randomized trials are required to provide more robust evidence about the effectiveness of dolutegravir.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"29952"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of key pathways and molecular players potentially involved in endometrial cancer metastasis through integrated bioinformatics analyses.","authors":"Maryam Rezazadeh, Shahla Danaei-Mehrabad, Nahideh Afshar Zakariya, Fatemeh Kazemi, Marziyeh Sadat Moslehian, Amin Tamadon, Reza Shirazi, Mahdi Mahdipour, Parvin Hakimi","doi":"10.34172/bi.30222","DOIUrl":"10.34172/bi.30222","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Endometrial cancer (EC) is a particularly frequent gynecological cancer, and metastasis is the leading cause of death in patients with EC. Using publicly accessible gene expression data, a bioinformatics study was carried out to increase our knowledge and reveal treatment targets for EC metastasis. This study aimed to identify new important molecular actors and clarify the molecular processes and pathways underlying EC metastasis.</p><p><strong>Methods: </strong>The GEOexplorer and R programming languages were used to analyze and visualize gene expression data from EC metastatic gene expression datasets, and differentially expressed genes (DEGs) and differentially expressed lncRNAs (DElncRNAs) were identified using bioinformatics with P-value thresholds of < 0.05, and |log2FC| > 1.5. KEGG pathway enrichment analysis and gene ontology enrichment was used to enrich the observed DEGs, protein-protein interactions were established, and hub genes were identified.</p><p><strong>Results: </strong>The findings revealed that DEGs were considerably enriched in a number of pathways, including the \"Pathways in cancer\", \"Breast cancer\", and \"<i>Rap1</i> signaling pathway.\" DEGs were also found to be involved in a number of biological processes, cellular components, and molecular activities. The PPI network included the hub genes <i>CTNNB1</i>, <i>FGFR3</i>, <i>ESR1</i>, and <i>SRSF3</i> as well as a number of DElncRNAs, such as <i>LINC01541, SNHG17, LINC00520, BHLHE22-AS1, LOC100509445, H19</i>, and <i>HOTAIRM1</i>.</p><p><strong>Conclusion: </strong>This study contributes to our understanding of the molecular processes driving EC metastasis, which may result in the development of new treatment targets and indicators for the early identification of EC metastasis. More studies are needed to validate these findings and to understand the functional roles of these key factors in EC metastasis.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30222"},"PeriodicalIF":2.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgY-mediated protection against <i>Vibrio cholerae</i> infection: Efficacy of avian antibodies targeting a chimeric recombinant protein.","authors":"Hasna Sadat Naghash Hoseini, Tooba Sadat Ahmadi, Seyed Latif Mousavi Gargari, Shahram Nazarian","doi":"10.34172/bi.30292","DOIUrl":"10.34172/bi.30292","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong><i>Vibrio cholerae</i>, the etiologic pathogen of diarrheal disease, prevails mainly in developing countries, transmitted through contaminated water or food. The unique genetic makeup and remarkable competency has prompted intensive research to unravel the bacterium virulence properties. Egg yolk immunoglobulins (IgY) have emerged as innovative biotherapeutics for both passive immunotherapy and prophylactic strategies.</p><p><strong>Methods: </strong>In the present study, we generated avian antibodies against a chimeric recombinant protein comprising OmpW-TcpA-CtxB (OTC) antigens from <i>V. cholerae</i>, and examined its efficacy against bacterial toxins and infection. The chimeric protein was expressed in <i>E. coli</i> BL21 (DE3) and purified using Ni-NTA affinity chromatography. Leghorn chickens were intramuscularly immunized with the recombinant protein and the purity of extracted IgYs was assessed through SDS-PAGE analysis. The immunoreactivity and specificity of anti-OTC-IgYs were evaluated through protein and whole-cell ELISA, and their ability to neutralize cholera toxin (CT) of <i>V. cholerae</i> was evaluated in Y1 cell line. Finally, the protective efficacy of orally administered anti-OTC-IgY was investigated in <i>V. cholerae</i>-infected infant mice.</p><p><strong>Results: </strong>Anti-OTC-IgY successfully neutralized the cytotoxic effects of CT at a concentration of 250 µg/mL. Oral administration of two 100 µg doses of anti-OTC-IgY and resulted in 60% and 20% survival rates in suckling mice infected with LD and 10 LD of <i>V. cholerae</i>, respectively.</p><p><strong>Conclusion: </strong>The anti-OTC-IgY antibodies exhibited significant immunoreactivity, toxin-neutralizing potency, and protective effects, establishing their potential as promising antimicrobials against the bacterial pathogenicity through passive immunotherapy.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30292"},"PeriodicalIF":2.2,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of microRNA-141-3p, E2F3, CDK3, and KAT2B overexpression on histologic tumor grade and metastasis status in untreated breast cancer tissues.","authors":"Sepideh Ebrahimian Vargahan, Mahmood Barati, Masoud Roudbari, Maryam Eini, Arshad Hosseini","doi":"10.34172/bi.30032","DOIUrl":"10.34172/bi.30032","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Increasing evidence has reported gene expression alterations in breast cancer (BC) tissues, necessitating their investigating to highlight the molecular basis of the disease development or progression. This study investigated the expression of miR-141, E2F3, CDK3, TP53, and KAT2B, and their association with histologic grade and metastasis in BC tissues.</p><p><strong>Methods: </strong>The RNA expression level of miR-141, E2F3, CDK3, TP53, and KAT2B genes was analyzed in 23 BC and 23 normal tissue samples by RT-qPCR. The associations of the expression level of these genes with clinicopathological features of the BC tissue samples were evaluated. The study also explored the correlation between RNA levels of genes and miR-141.</p><p><strong>Results: </strong>Expression of miR-141, E2F3, CDK3, and KAT2B demonstrated significantly higher levels in BC tumor than normal tissues. TP53 expression showed an increase in tumor compared to normal tissues, although it was insignificant. Moreover, increased RNA expression of miR-141, E2F3, CDK3, and KAT2B corresponded to the advanced stage and regional metastasis of BC. Additionally, the results demonstrated a significant correlation between RNA expression levels of miR-141 with CDK3 and E2F3 with KAT2B.</p><p><strong>Conclusion: </strong>Our findings highlighted clinicopathologic indicators that were relevant to aggressive BC. Besides, Correlations between overexpression of miR-141, E2F3, CDK3, and KAT2B in BC tissues suggest regulatory effects. Taken together, it seems results of this study could provide evidence that dysregulation of gene expression contributes significantly to unveiling the underlying molecular basis of BC.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30032"},"PeriodicalIF":2.2,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous effect of miR-21 suppression and miR-143 restoration on inhibition of proliferation and migration in SW-480 colorectal cancer cells.","authors":"Maryam Tohidast, Mohammad Amini, Mohammad Amin Doustvandi, Seyed Samad Hosseini, Farzaneh Bilan, Nazila Mozammel, Pouryia Sameti, Amir Ali Mokhtarzadeh, Behzad Baradaran","doi":"10.34172/bi.30255","DOIUrl":"10.34172/bi.30255","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Colorectal cancer (CRC) is regarded as a serious global issue and is presently ranked second in the classification of gastrointestinal (GI) malignancies, with fast incidence and high mortality patterns. As the key \"gene expression regulators\", miRNAs critically contribute to tumor progression and development. For example, miR-21 (an oncomiR) and miR-143 (a tumor suppressor) are dysregulated through colorectal tumorigenesis. Accordingly, this study assesses the concomitant therapeutic impacts of \"miR-21 suppression\" (anti-miR-21) and \"miR-143 restoration\" (miR-143) on CRC cell proliferation and migration.</p><p><strong>Methods: </strong>SW-480 cell lines (with overexpressed \"miR-21\" and downregulated \"miR-143\") were transfected via \"anti-miR-21\" and \"miR-143\" mimics, either independently or in combination. Next, cell viability assessment was performed through MTT assay. Then, apoptosis induction was examined with \"Annexin V-FITC Kit\", and via Propidium Iodide (PI) assay and DAPI staining. In the next step, \"cell cycle condition\" and \"autophagy induction\" were studied through flow cytometry. \"Wound-healing assay\" and \"clonogenic assay\" were employed to investigate the migration and proliferation of tumor cells. Ultimately, qRT-PCR was utilized to quantify the intensity of the effects of \"anti-miR-21\" and \"miR-143\" on gene expression profiles.</p><p><strong>Results: </strong>Downregulation of \"miR-21\" expression and overexpression of \"miR-143\" were found to synergistically reduce the viability (while elevating apoptosis) of SW-480 cells by modulating <i>Bcl-2</i> and <i>Bax</i> expression profiles. Combined therapy increased the number of cells in the sub-G1 phase and reduced cell proliferation by modulating expression levels of PTEN and AKT-1. Additionally, miR-21 suppression and miR-143 restoration concomitantly reduced cell migration by modulating the expression of <i>MMP-9</i>.</p><p><strong>Conclusion: </strong>Considering anti-cancer effects on cell growth, survival, and migration, it can be concluded that the concomitant suppression of \"anti-miR-21\" and \"miR-143 restoration\" might be introduced as a promising method for the therapy of CRC.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30255"},"PeriodicalIF":2.2,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: A systematic review of randomized controlled trials.","authors":"Ika Rahayu, Nur Arfian, Christina Yeni Kustanti, Mae Sri Hartati Wahyuningsih","doi":"10.34172/bi.30129","DOIUrl":"10.34172/bi.30129","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Oxidative stress plays a central role in the pathophysiology of diabetes mellitus and its complications, including diabetic nephropathy. Excessive production of reactive oxygen species (ROS) alters renal metabolic pathways, leading to inflammation, endothelial dysfunction, and fibrosis, ultimately resulting in end-stage renal disease (ESRD). Studies have shown that exogenous antioxidants can improve the pathophysiological condition of patients with diabetic nephropathy. Objective: This systematic review aims to investigate the types of antioxidant agents that inhibit the development of diabetic nephropathy and the effectiveness of antioxidant agent interventions to repair kidney structure and function.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A systematic review of randomized controlled trials that examined the role of antioxidants in improving diabetic nephropathy was conducted. The literature search was performed on PubMed, ScienceDirect, and EBSCO. The inclusion criteria covered articles on the antioxidant activity of herbal extracts and compounds that inhibit the progression of diabetic nephropathy in humans. In addition, the articles were written in English and published between 2012 and 2022. The reporting of the systematic review followed the Preferred Reporting Elements for Systematic Review and Meta-Analysis (PRISMA) guideline. The full texts of all potentially relevant systematic reviews were assessed for quality using the Risk of Bias 2 (RoB 2) tool.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 2,367 articles were identified in the three databases, of which only 15 articles met the inclusion criteria. Antioxidant agents that inhibit diabetic nephropathy can be classified as single antioxidants (silymarin, baicalin, epigallocatechin gallate, vitamin E, selenium, curcumin, α-lipoic acid, and tocotrienol-rich vitamin E) and combined antioxidants (α-lipoic acid with vitamin B6, and resveratrol with losartan). Antioxidant agents have been shown to reduce oxidative stress and inflammation, but their role in the progression of fibrosis remains unclear. The oxidative stress marker MDA was significantly reduced by silymarin, curcumin, vitamin E, tocotrienol-rich vitamin E, selenium, ALA, vitamin B, resveratrol and losartan. Silymarin was found to be the most effective (-3.43 µmol/L; 6.02 to 0.83). Compared to silymarin and epigallocatechin gallate, vitamin E was more effective (at -35.4 ng/L; &lt;i&gt;P&lt;/i&gt; &lt; 0.001) in reducing inflammation by decreasing TNF-α levels. In addition, tocotrienol-rich vitamin E, silymarin, baicalin, and selenium showed a decrease TGF-β levels, but did not show statistically significant differences between the placebo and intervention groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Potential antioxidant agents, such as flavonoids, vitamins, fatty acids, and antioxidant minerals, were examined in this systematic review. These agents contribute to reducing markers of oxidative stress and hypergly","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30129"},"PeriodicalIF":2.2,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microfluidics as a promising technology for personalized medicine.","authors":"Zahra Oushyani Roudsari, Zahra Esmaeili, Nafiseh Nasirzadeh, Saeed Heidari Keshel, Farshid Sefat, Hassan Bakhtyari, Samad Nadri","doi":"10.34172/bi.29944","DOIUrl":"10.34172/bi.29944","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Due to the recent advances in biomedicine and the increasing understanding of the molecular mechanism of diseases, healthcare approaches have tended towards preventive and personalized medicine. Consequently, in recent decades, the utilization of interdisciplinary technologies such as microfluidic systems had a significant increase to provide more accurate high throughput diagnostic/therapeutic methods.</p><p><strong>Methods: </strong>In this article, we will review a summary of innovations in microfluidic technologies toward improving personalized biomolecular diagnostics, drug screening, and therapeutic strategies.</p><p><strong>Results: </strong>Microfluidic systems by providing a controllable space for fluid flow, three-dimensional growth of cells, and miniaturization of molecular experiments are useful tools in the field of personalization of health and treatment. These conditions have enabled the potential to carry out studies like; disease modeling, drug screening, and improving the accuracy of diagnostic methods.</p><p><strong>Conclusion: </strong>Microfluidic devices have become promising point-of-care (POC) and personalized medicine instruments due to their ability to perform diagnostic tests with small sample volumes, cost reduction, high resolution, and automation.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"29944"},"PeriodicalIF":2.2,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR-based gene editing in plants: Focus on reagents and their delivery tools.","authors":"Vida Ebrahimi, Atieh Hashemi","doi":"10.34172/bi.30019","DOIUrl":"10.34172/bi.30019","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>CRISPR-Cas9 technology has revolutionized plant genome editing, providing precise and efficient methods for genetic modification. This study focuses on the advancements and delivery of CRISPR-Cas9 in plant gene editing.</p><p><strong>Methods: </strong>A comprehensive search in scientific databases, including PubMed, ScienceDirect, and Google Scholar, was conducted to gather information on CRISPR-Cas9 gene editing and its delivery in precise gene modification in plants.</p><p><strong>Results: </strong>The evolving landscape of CRISPR nucleases has led to the development of innovative technologies, enhancing plant research. However, successful editing is contingent on efficient delivery of genome engineering reagents. CRISPR-based gene editing in plants utilizes diverse delivery methods: <i>Agrobacterium</i>-mediated transformation for bacterial transfer, biolistic transformation for physical gene insertion, electroporation for direct gene entry, expression of developmental regulators for gene expression modulation, and tobacco rattle virus as a viral vector, each offering distinct advantages for precise and efficient genetic modification in plants.</p><p><strong>Conclusion: </strong>CRISPR-Cas9 gene editing stands as a pivotal advancement in plant genetics, offering precise gene manipulation with applications in agriculture and biotechnology. The continuous refinement of reagent delivery tools reinforces CRISPR-Cas9's transformative role in plant genome editing, with significant implications for broader scientific applications.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30019"},"PeriodicalIF":2.2,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising leads against lung cancer from the plants in Lamiaceae family.","authors":"Alireza Rahimlouy Aghdam, Sanaz Hamedeyazdan","doi":"10.34172/bi.30074","DOIUrl":"10.34172/bi.30074","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Ceaselessly, management of cancer has been the major global challenge for healthcare professionals. As regards, lung cancer (LC) has been introduced as the second most common form of cancer in both men and women, taking the lives of more than a million people each year, statistically holding the highest mortality rate among all cancer types. Although much effort has been made for the management of LC, current therapies are quite ineffective. With reference to the fact that the most current chemotherapeutic agents for LC are of plant origin, the authors hereby collected the acclaimed plants from the Lamiaceae family which have shown remarkable activity against LC.</p><p><strong>Methods: </strong>The incorporated papers were published between the years of 1997 and 2023. The principal search keywords for this review article were \"lung cancer\", \"Lamiaceae\", \"cytotoxic effect\", \"anti-tumor\" and \"anti-proliferative\" in Medline, Springer, Scopus, ScienceDirect and Google Scholar databases.</p><p><strong>Results: </strong>To the furthest extent, different responsible mechanism(s) of action for the anti-cancer properties of each plant are discussed. The respected IC₅₀ values for plant extracts, essential oils or pure isolated compounds are underlined as well.</p><p><strong>Conclusion: </strong>Many plants and isolated relative phytochemicals have shown exceptional anti-cancer potency against LC; nonetheless, they still remain undisclosed. We believe that this assembled data would globally inspire scientists on the passing way of LC treatment.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30074"},"PeriodicalIF":2.2,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}